Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
Explore this paper's citation graph
Summary
Re-treatment with I-131 tositumomab following a previous response can produce second responses that can be durable, with no clinical factors predicting response or its duration.
- Type
- article
- Published
- 2005-11-01
- Cited by
- 92
- References
- 16
- OpenAlex
- https://openalex.org/W16204016
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:38440938
Keywords
Computer science
References
- Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.
- Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
- Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
- 131I-tositumomab therapy as initial treatment for follicular lymphoma.
- Antibody-directed therapies for hematological malignancies.
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
- Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
- Natural history of and therapy for the indolent non-Hodgkin's lymphomas.
- Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.
- Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
- The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
- Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
- Follicular lymphoma: prognostic factors for response and survival.
- The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.
- Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
- Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Cited by
- Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report
- Advanced-Stage Follicular Lymphoma in the Rituximab Era
- Radioimmunotherapy for B-cell non-hodgkin lymphomas.
- Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
- Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
- Clinical radioimmunotherapy—the role of radiobiology
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies
- Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin’s Lymphoma
- Review of antibody-based immunotherapy in the treatment of non-Hodgkin lymphoma and patterns of use.
- Radioactive Antibodies: A Historical Review of Selective Targeting and Treatment of Cancer
- Review of clinical radioimmunotherapy
- Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
- Follicular lymphoma international prognostic index
- Aiming at a Curative Strategy for Follicular Lymphoma
- Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
- Pruritus in Patients Treated with Targeted Cancer Therapies: Systematic Review and Meta-Analysis
- Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.
- Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides
- Follicular lymphoma: 2011 update on diagnosis and management
- Follicular lymphoma: today’s treatments and tomorrow’s targets
Related papers
No related papers recorded.